<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer New York</PublisherName>
    <PublisherLocation>New York, NY</PublisherLocation>
    <PublisherImprintName>Springer</PublisherImprintName>
  </PublisherInfo>
  <Book Language="En">
    <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
      <BookID>978-1-60327-829-4</BookID>
      <BookTitle>Drug Management of Prostate Cancer</BookTitle>
      <BookDOI>10.1007/978-1-60327-829-4</BookDOI>
      <BookTitleID>158057</BookTitleID>
      <BookPrintISBN>978-1-60327-831-7</BookPrintISBN>
      <BookElectronicISBN>978-1-60327-829-4</BookElectronicISBN>
      <BookChapterCount>37</BookChapterCount>
      <BookCopyright>
        <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
        <CopyrightYear>2010</CopyrightYear>
      </BookCopyright>
      <BookSubjectGroup>
        <BookSubject Code="SCH" Type="Primary">Medicine &amp; Public Health</BookSubject>
        <BookSubject Code="SCH33160" Priority="1" Type="Secondary">Oncology</BookSubject>
        <BookSubject Code="SCH62002" Priority="2" Type="Secondary">Urology</BookSubject>
        <BookSubject Code="SCH33002" Priority="3" Type="Secondary">Internal Medicine</BookSubject>
        <SubjectCollection Code="SUCO11650">Medicine</SubjectCollection>
      </BookSubjectGroup>
    </BookInfo>
    <BookHeader>
      <EditorGroup>
        <Editor AffiliationIDS="AffID1">
          <EditorName DisplayOrder="Western">
            <GivenName>William D.</GivenName>
            <FamilyName>Figg</FamilyName>
          </EditorName>
          <Contact>
            <Phone>301402-3622</Phone>
            <Fax>301402-8606</Fax>
            <Email>wdfigg@helix.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID2">
          <EditorName DisplayOrder="Western">
            <GivenName>Cindy H.</GivenName>
            <FamilyName>Chau</FamilyName>
          </EditorName>
          <Contact>
            <Email>chauc@mail.nih.gov</Email>
          </Contact>
        </Editor>
        <Editor AffiliationIDS="AffID3">
          <EditorName DisplayOrder="Western">
            <GivenName>Eric J.</GivenName>
            <FamilyName>Small</FamilyName>
          </EditorName>
          <Contact>
            <Phone>415/353-7171</Phone>
            <Email>smalle@medicine.ucsf.edu</Email>
          </Contact>
        </Editor>
        <Affiliation ID="AffID1">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID2">
          <OrgDivision>Medical Oncology Branch</OrgDivision>
          <OrgName>NIH National Cancer Institute</OrgName>
          <OrgAddress>
            <Street>Rockville Pike 9000</Street>
            <City>Bethesda</City>
            <Postcode>20892</Postcode>
            <State>Maryland</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
        <Affiliation ID="AffID3">
          <OrgDivision>School of Medicine, Dept. Urology</OrgDivision>
          <OrgName>University of California, San Francisco</OrgName>
          <OrgAddress>
            <Street>Divisadero Street 1600</Street>
            <City>San Francisco</City>
            <Postcode>94115</Postcode>
            <State>California</State>
            <Country>USA</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </BookHeader>
    <Part ID="Part4">
      <PartInfo OutputMedium="All" TocLevels="0">
        <PartID>4</PartID>
        <PartNumber>Part III</PartNumber>
        <PartSequenceNumber>4</PartSequenceNumber>
        <PartTitle>Angiogenesis</PartTitle>
        <PartChapterCount>5</PartChapterCount>
        <PartContext>
          <BookID>978-1-60327-829-4</BookID>
          <BookTitle>Drug Management of Prostate Cancer</BookTitle>
        </PartContext>
      </PartInfo>
      <Chapter ID="Chap17" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterOnly" OutputMedium="All" TocLevels="0">
          <ChapterID>17</ChapterID>
          <ChapterNumber>Chapter 17</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-829-4_17</ChapterDOI>
          <ChapterSequenceNumber>17</ChapterSequenceNumber>
          <ChapterTitle Language="En">Principles of Antiangiogenic Therapy</ChapterTitle>
          <ChapterFirstPage>197</ChapterFirstPage>
          <ChapterLastPage>205</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2010</CopyrightYear>
          </ChapterCopyright>
          <ChapterHistory>
            <RegistrationDate>
              <Year>2010</Year>
              <Month>4</Month>
              <Day>16</Day>
            </RegistrationDate>
            <OnlineDate>
              <Year>2010</Year>
              <Month>8</Month>
              <Day>3</Day>
            </OnlineDate>
          </ChapterHistory>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <PartID>4</PartID>
            <BookID>978-1-60327-829-4</BookID>
            <BookTitle>Drug Management of Prostate Cancer</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff1_17" CorrespondingAffiliationID="Aff1_17">
              <AuthorName DisplayOrder="Western">
                <GivenName>Cindy</GivenName>
                <GivenName>H.</GivenName>
                <FamilyName>Chau</FamilyName>
              </AuthorName>
              <Contact>
                <Email>chauc@mail.nih.gov</Email>
              </Contact>
            </Author>
            <Author>
              <AuthorName DisplayOrder="Western">
                <GivenName>William</GivenName>
                <GivenName>D.</GivenName>
                <FamilyName>Figg</FamilyName>
              </AuthorName>
            </Author>
            <Affiliation ID="Aff1_17">
              <OrgDivision>Medical Oncology Branch, Center for Cancer Research</OrgDivision>
              <OrgName>National Cancer Institute/NIH</OrgName>
              <OrgAddress>
                <Street>9000 Rockville Pike</Street>
                <City>Bethesda</City>
                <State>MD</State>
                <Postcode>20892</Postcode>
                <Country>USA</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1_17" Language="En" OutputMedium="All">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Angiogenesis is a critical process to both tumor growth and metastasis in prostate cancer. The markers of angiogenesis in prostate cancer have been identified and could potentially provide prognostic information in addition to clinicopathological data and patient outcome. Promising preclinical studies have led to the initiation of phase I/II studies of antiangiogenic therapy in combination with docetaxel-based chemotherapy in patients with castration-resistant prostate cancer. This chapter describes the mechanisms of the angiogenic process, establishes its role in prostate cancer, and discusses the markers of angiogenesis in prostate cancer, in an attempt to provide an overall understanding of the basic principles of antiangiogenic therapy.</Para>
          </Abstract>
          <KeywordGroup Language="En" OutputMedium="All">
            <Heading>Keywords</Heading>
            <Keyword>Angiogenesis</Keyword>
            <Keyword>Angiogenic switch</Keyword>
            <Keyword>Angiogenesis inhibitor</Keyword>
            <Keyword>Microvessel density</Keyword>
            <Keyword>Antiangiogenic therapy</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Cancer metastasis occurs when cancer cells break away from the primary tumor and penetrate into lymphatic and blood vessels, circulating through the bloodstream to invade and grow in the normal tissues elsewhere. Understanding the metastatic process requires characterizing the growth and invasion of solid tumors and identifying the environmental cues that trigger and/or govern this event. Early cancer researchers investigating the conditions necessary for cancer metastasis observed that one of the critical events required for tumor growth is an increased vascularization and the formation of a new network of blood vessels called <Emphasis Type="Italic">angiogenesis</Emphasis>. Over 70 years ago, the existence of tumor-derived factors responsible for promoting new vessel growth was postulated [<CitationRef CitationID="CR1_17">1</CitationRef>], and it was found that tumor growth is essentially dependent on vascular induction and the development of a neovascular supply [<CitationRef CitationID="CR2_17">2</CitationRef>]. By the late 1960s, Dr. Judah Folkman and colleagues had begun the search for a tumor angiogenesis factor [<CitationRef CitationID="CR3_17">3</CitationRef>]. In his landmark report, Folkman proposed that inhibition of angiogenesis by means of holding tumors in a nonvascularized dormant state would be an effective strategy to treat human cancer, and hence laid the groundwork for the concept behind the development of “antiangiogenic” drugs [<CitationRef CitationID="CR4_17">4</CitationRef>]. This fostered the search for angiogenic factors, regulators of angiogenesis, and antiangiogenic molecules over the next three decades and shed light on angiogenesis as an important therapeutic target for the treatment of cancer and other diseases.</Para>
            <Para TextBreak="No">Successful development and clinical translation of antiangiogenic agents depends on understanding the biology of angiogenesis in tumor progression and the regulatory proteins that govern this angiogenic process. This chapter provides an overview of the principles of antiangiogenic therapy by presenting the mechanisms behind the angiogenic process followed by a discussion of the markers of angiogenesis in prostate cancer. The next chapters in this section cover the investigational antiangiogenic agents used in the treatment of metastatic castration-resistant prostate cancer (CRPC) as well as the pharmacogenetics of angiogenesis.</Para>
          </Section1>
          <Section1 ID="Sec2">
            <Heading>Mechanisms of the Angiogenic Process</Heading>
            <Section2 ID="Sec3">
              <Heading>Angiogenic Switch and Regulatory Proteins</Heading>
              <Para TextBreak="No">Tumor development and progression depends on angiogenesis. Recruitment of new blood vessels to the tumor site is required for delivery of nutrients and oxygen to the cancerous growths and removal of waste products [<CitationRef CitationID="CR5_17">5</CitationRef>]. Cancer cells promote angiogenesis at an early stage of tumorigenesis beginning with the release of molecules that send signals to the surrounding normal host tissue and stimulating the migration of microvascular endothelial cells (ECs) in the direction of the angiogenic stimulus. These angiogenic factors not only mediate EC migration but also EC proliferation and microvessel formation in tumors undergoing the switch to the angiogenic phenotype [<CitationRef CitationID="CR6_17">6</CitationRef>].</Para>
              <Para TextBreak="No">Experimental evidence for this “angiogenic switch” was observed when hyperplastic islets in transgenic mice (RIP-Tag model) switch from small (&lt;1 mm), white microscopic dormant tumors to red, rapidly growing tumors [<CitationRef CitationID="CR6_17">6</CitationRef>]. Dormant tumors have been discovered during autopsies of individuals who died of causes other than cancer [<CitationRef CitationID="CR7_17">7</CitationRef>]. These autopsy studies suggest that the vast majority of microscopic, in situ cancers never switch to the angiogenic phenotype during a normal lifetime. Such incipient tumors are usually not neovascularized and can remain harmless to the host for long periods of time as microscopic lesions that are in a state of dormancy [<CitationRef CitationID="CR8_17">8</CitationRef>, <CitationRef CitationID="CR9_17">9</CitationRef>]. These nonangiogenic tumors cannot expand beyond the initial microscopic size and become clinically detectable, lethal tumors until they have switched to the angiogenic phenotype [<CitationRef CitationID="CR10_17">10</CitationRef>–<CitationRef CitationID="CR12_17">12</CitationRef>] through neovascularization and/or blood vessel co-option [<CitationRef CitationID="CR13_17">13</CitationRef>]. Depending on the tumor type and the environment, this switch can occur at different stages of the tumor progression pathway and ultimately depends on a net balance of positive and negative regulators. Thus, the angiogenic phenotype may result from the production of growth factors by tumor cells and/or the downregulation of negative modulators.</Para>
              <Para TextBreak="No">Changes in this angiogenic balance affecting the levels of activator and inhibitor molecules dictate whether an EC will be in a quiescent or an angiogenic state. Normally, the inhibitors predominate, thereby blocking growth. Should a need for new blood vessels arise, the balance will shift in favor of the angiogenic state with an increase in the amount of activators and a decrease in inhibitors. This prompts the activation, growth, and division of vascular ECs, resulting in the formation of new blood vessels. The activated ECs produce and release matrix metalloproteinases (MMPs) into the surrounding tissue. These degradative enzymes breakdown the extracellular matrix to allow the ECs to migrate into the surrounding tissues and organize themselves into hollow tubes that eventually evolve into a mature network of blood vessels.</Para>
              <Para TextBreak="No">Proangiogenic factors or positive regulators of angiogenesis include vascular endothelial growth factor (VEGF), basic fibroblast growth factor, (bFGF), platelet-derived growth factor (PDGF), placental growth factor (PlGF), transforming growth factor-β, pleiotrophins, and others [<CitationRef CitationID="CR14_17">14</CitationRef>]. VEGF (also known as vascular permeability factor) is a potent proangiogenic growth factor and its expression is upregulated by most cancer-cell types. It stimulates endothelial-cell proliferation, migration, and survival as well as induces increased vascular permeability. The different forms of VEGF bind to transmembrane tyrosine kinase receptors (RTKs) on ECs: VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1), or VEGFR3 (Flt-4) [<CitationRef CitationID="CR15_17">15</CitationRef>]. This results in receptor dimerization, activation, and autophosphorylation of the tyrosine kinase domain, thereby triggering downstream signaling pathways. bFGF is present in basement membranes and in the subendothelial extracellular matrix of blood vessels. When activated, it can mediate the formation of new blood vessels. Other signaling molecules that may represent attractive therapeutic targets include PDGF and angiopoietin-2 (Ang-2). PDGF-B/PDGF receptor-β plays an important role in the recruitment of pericytes and maturation of the microvasculature [<CitationRef CitationID="CR16_17">16</CitationRef>]. Ang-2 (which binds the Tie-2 receptor) is mostly expressed in tumor-induced neovasculature, whereby its selective inhibition results in reduced EC proliferation [<CitationRef CitationID="CR17_17">17</CitationRef>].</Para>
              <Para TextBreak="No">Activation of the hypoxia-inducible factor-1α (HIF-1α) via tumor-associated hypoxic conditions is also involved in the upregulation of several angiogenic factors [<CitationRef CitationID="CR18_17">18</CitationRef>]. The angiogenic switch can downregulate angiogenesis suppressor proteins that include endostatin, angiostatin, thrombospondin, and others (reviewed in ref. [<CitationRef CitationID="CR19_17">19</CitationRef>, <CitationRef CitationID="CR20_17">20</CitationRef>]). Most notable is the link between many oncogenes and angiogenesis and the significant role oncogenes play in driving the angiogenic switch. These proangiogenic oncogenes not only induce the expression of stimulators but may also downregulate inhibitors of angiogenesis (reviewed in ref. [<CitationRef CitationID="CR21_17">21</CitationRef>]).</Para>
            </Section2>
            <Section2 ID="Sec4">
              <Heading>Endogenous Inhibitors of Angiogenesis</Heading>
              <Para TextBreak="No">The first angiogenesis inhibitor was reported in 1980 and involved low-dose administration of interferon-alpha [<CitationRef CitationID="CR22_17">22</CitationRef>–<CitationRef CitationID="CR24_17">24</CitationRef>]. Over the next decade, several compounds were discovered to have potent antiangiogenic activity and included protamine and platelet-factor 4 [<CitationRef CitationID="CR25_17">25</CitationRef>], trahydrocortisol [<CitationRef CitationID="CR26_17">26</CitationRef>], and the fumagillin analogue TNP-470 [<CitationRef CitationID="CR27_17">27</CitationRef>]. Additionally, at least 28 endogenous angiogenesis inhibitors have been identified to date [<CitationRef CitationID="CR19_17">19</CitationRef>, <CitationRef CitationID="CR20_17">20</CitationRef>].</Para>
              <Para TextBreak="No">The infrequency of microscopic in situ tumors that actually undergo the angiogenic switch (&lt;1%) suggests that naturally occurring endogenous inhibitors exist in the body to defend against the angiogenic switch in pathological conditions and limit physiological angiogenesis [<CitationRef CitationID="CR8_17">8</CitationRef>]. These circulating endogenous inhibitors could also prevent microscopic metastases from growing into visible tumors. The discovery of angiostatin, an internal fragment of plasminogen, first revealed that an angiogenesis inhibitory peptide could be enzymatically released from a parent protein that lacked this inhibitory property [<CitationRef CitationID="CR28_17">28</CitationRef>]. Soon thereafter endostatin, an internal fragment of collagen XVIII, demonstrated for the first time that a basement-membrane collagen contained an antiangiogenic peptide [<CitationRef CitationID="CR29_17">29</CitationRef>]. Endostatin is the most well-studied endogenous angiogenesis inhibitor (reviewed in ref. [<CitationRef CitationID="CR30_17">30</CitationRef>]). Other potent endogenous angiogenesis inhibitors include thrombospondin-1 (TSP-1) [<CitationRef CitationID="CR31_17">31</CitationRef>] and tumstatin, a 232-amino acid antiangiogenic peptide in the alpha3 chain of collagen type IV [<CitationRef CitationID="CR32_17">32</CitationRef>]. The discovery that these endogenous angiogenesis inhibitors can suppress the growth of primary tumors raises the possibility that such inhibitors might also be able to slow tumor metastasis. Indeed inhibition of angiogenesis by angiostatin significantly reduced the rate of metastatic spread.</Para>
              <Para TextBreak="No">Perhaps the most compelling genetic evidence that endogenous inhibitors suppress pathologic angiogenesis was observed in studies using mice deficient in tumstatin, endostatin, or TSP-1 [<CitationRef CitationID="CR33_17">33</CitationRef>]. These experiments demonstrate that normal physiological levels of the inhibitors can retard the tumor growth, and that their absence leads to enhanced angiogenesis and increased tumor growth by two- to threefold. Tumors grow twofold faster in the tumstatin/TSP-1 double-knockout mice compared with either the tumstatin- or the TSP-1-deficient mice. Additionally, tumor growth in transgenic mice overexpressing endostatin specifically in the ECs (a 1.6-fold increase in the circulating levels) is threefold slower than the tumor growth in wild-type mice. Collectively, these results strongly suggest that endogenous inhibitors of angiogenesis can act as endothelium-specific tumor suppressors.</Para>
              <Para TextBreak="No">The connection between a tumor suppressor protein and angiogenesis is best illustrated by the classic tumor suppressor p53. p53 is known to link the biology of the cell cycle to tumorigenesis and for its role in regulating tumor cell proliferation. However, p53 can also inhibit angiogenesis by increasing the expression of TSP-1 [<CitationRef CitationID="CR34_17">34</CitationRef>], by repressing VEGF [<CitationRef CitationID="CR35_17">35</CitationRef>] and bFGF binding protein [<CitationRef CitationID="CR36_17">36</CitationRef>], and by degrading HIF-1 [<CitationRef CitationID="CR37_17">37</CitationRef>], which blocks downstream induction of VEGF expression. Furthermore, a recent study revealed that p53-mediated inhibition of angiogenesis occurs in part via the antiangiogenic activity of endostatin and tumstatin [<CitationRef CitationID="CR38_17">38</CitationRef>]. This landmark finding clearly demonstrates that p53 not only controls cell proliferation but can also repress tumor angiogenesis through enzymatic mobilization of these endogenous angiogenesis inhibitor proteins to prevent ECs from being recruited into the dormant, microscopic tumors and thereby preventing the switch to the angiogenic phenotype [<CitationRef CitationID="CR39_17">39</CitationRef>]. It remains to be established whether other angiogenesis inhibitors are regulated by p53 or by other tumor suppressor genes.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec5">
            <Heading>Angiogenesis and Prostate Cancer</Heading>
            <Para TextBreak="No">The significance of angiogenesis in prostate cancer is well established with the identification of several markers of angiogenesis in CaP, with microvessel density (MVD) and VEGF being two of the most commonly measured (Table <InternalRef RefID="Tab1">17.1</InternalRef>). In general, many studies have demonstrated the direct correlation of angiogenesis with Gleason score, pathological stage, progression, metastasis, and survival [<CitationRef CitationID="CR40_17">40</CitationRef>, <CitationRef CitationID="CR41_17">41</CitationRef>]. Weidner et al. determined that patients with metastatic prostate cancer have a higher mean MVD than those without metastasis [<CitationRef CitationID="CR42_17">42</CitationRef>]. VEGF expression is significantly increased in prostate tumors (relative to normal tissue), which directly correlates with MVD, tumor stage and grade, and disease-specific survival in patients with CaP [<CitationRef CitationID="CR43_17">43</CitationRef>]. A strong expression of VEGF is detected in neuroendocrine-differentiated tumor cells [<CitationRef CitationID="CR43_17">43</CitationRef>], and the coexpression of VEGF with MMP-2 and MMP-9 further increases the malignant potential of prostate tumors [<CitationRef CitationID="CR44_17">44</CitationRef>]. Serum VEGF levels are significantly higher in patients with metastatic prostate cancer than in patients with localized disease [<CitationRef CitationID="CR45_17">45</CitationRef>].<Table Float="Yes" ID="Tab1">
                <Caption Language="En">
                  <CaptionNumber>Table 17.1</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Markers of angiogenesis in prostate cancer</SimplePara>
                  </CaptionContent>
                </Caption>
                <tgroup cols="2">
                  <colspec colname="c1" colnum="1"/>
                  <colspec colname="c2" colnum="2"/>
                  <thead>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Markers of angiogenesis</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>References</SimplePara>
                      </entry>
                    </row>
                  </thead>
                  <tbody>
                    <row>
                      <entry colname="c1">
                        <SimplePara>MVD (factor VIII; CD34)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR40_17">40</CitationRef>, <CitationRef CitationID="CR41_17">41</CitationRef>, <CitationRef CitationID="CR43_17">43</CitationRef>, <CitationRef CitationID="CR52_17">52</CitationRef>, <CitationRef CitationID="CR53_17">53</CitationRef>, <CitationRef CitationID="CR55_17">55</CitationRef>, <CitationRef CitationID="CR59_17">59</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>VEGF</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR43_17">43</CitationRef>, <CitationRef CitationID="CR44_17">44</CitationRef>, <CitationRef CitationID="CR47_17">47</CitationRef>, <CitationRef CitationID="CR48_17">48</CitationRef>, <CitationRef CitationID="CR53_17">53</CitationRef>, <CitationRef CitationID="CR59_17">59</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Serum VEGF</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR45_17">45</CitationRef>, <CitationRef CitationID="CR84_17">84</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Matrix metalloproteinases (MMP-2, MMP-9)</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR44_17">44</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>bFGF</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR47_17">47</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Serum bFGF</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR46_17">46</CitationRef>, <CitationRef CitationID="CR84_17">84</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>IL-8</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR50_17">50</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Serum IL-8</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR49_17">49</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Endoglin</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR51_17">51</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>p53</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR52_17">52</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Tumor-associated macrophages</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR52_17">52</CitationRef>, <CitationRef CitationID="CR54_17">54</CitationRef>, <CitationRef CitationID="CR55_17">55</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Tissue factor</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR56_17">56</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                    <row>
                      <entry colname="c1">
                        <SimplePara>Hypoxia-inducible factor 1</SimplePara>
                      </entry>
                      <entry colname="c2">
                        <SimplePara>[<CitationRef CitationID="CR57_17">57</CitationRef>, <CitationRef CitationID="CR58_17">58</CitationRef>]</SimplePara>
                      </entry>
                    </row>
                  </tbody>
                </tgroup>
              </Table>
            </Para>
            <Para TextBreak="No">Several additional growth factors are thought to enhance angiogenesis in prostate cancer. Although bFGF is a known endothelial mitogen, the prognostic role of bFGF and its receptor (FGFR1) in prostate cancer has been controversial. Previous studies have shown that serum bFGF levels are elevated in most men with CaP and had a relatively high sensitivity (83%) in detecting carcinoma in patients with serum prostate-specific antigen (PSA) levels below 4.0 ng/mL as well as in differentiating between patients with local and advanced disease [<CitationRef CitationID="CR46_17">46</CitationRef>]. Others have reported that while serum bFGF and VEGF were not helpful in differentiating between patients with benign and malignant prostatic disease [<CitationRef CitationID="CR47_17">47</CitationRef>], together they are correlated with poor prostate cancer survival [<CitationRef CitationID="CR48_17">48</CitationRef>]. Serum levels of interleukin-8 (IL-8) are significantly elevated in men with prostate cancer and bone metastases compared with patients with localized disease [<CitationRef CitationID="CR49_17">49</CitationRef>], and the expression of IL-8 correlates directly with Gleason score, tumor stage, and MVD [<CitationRef CitationID="CR50_17">50</CitationRef>]. Endoglin, a receptor for TGF-β that is expressed on proliferating ECs, has direct association with MVD, Gleason score, tumor stage and CaP metastasis and is a prognostic marker for survival in a subgroup of patients with Gleason score 5, 6, and 7 tumors [<CitationRef CitationID="CR51_17">51</CitationRef>]. While mutations in the <Emphasis Type="Italic">p53</Emphasis> gene have been associated with increased MVD and higher stage and grade of CaP [<CitationRef CitationID="CR52_17">52</CitationRef>], the regulation of VEGF in CaP appears to be independent of p53 expression [<CitationRef CitationID="CR53_17">53</CitationRef>]. Other markers that have shown a positive association with angiogenesis in prostate cancer include tumor-associated macrophages [<CitationRef CitationID="CR54_17">54</CitationRef>, <CitationRef CitationID="CR55_17">55</CitationRef>] and tissue factor [<CitationRef CitationID="CR56_17">56</CitationRef>].</Para>
            <Para TextBreak="No">The role of HIF in prostate cancer development and its transition to a metastatic and castrate-resistant state remain to be elucidated. HIF, a key mediator of VEGF expression, is upregulated in the majority of prostate tumor tissues, compared with normal and benign prostate tissues, and its expression is induced in prostate cancer in situ [<CitationRef CitationID="CR57_17">57</CitationRef>]. Immunohistochemical studies of HIF-1α in clinical specimens of high-grade prostate intraepithelial neoplasia lesions, considered the precursor of a majority of invasive prostate adenocarcinoma, show an increase in HIF-1α relative to the respective normal epithelium, stromal cells, and benign prostatic hyperplasia [<CitationRef CitationID="CR58_17">58</CitationRef>]. These findings suggest that upregulation of HIF-1α is an early event in prostate carcinogenesis. Additionally, studies have shown that complete androgen blockade downregulates VEGF expression possibly via inhibition of HIF-1 with concomitant upregulation of thrombospondin and induction of EC apoptosis [<CitationRef CitationID="CR59_17">59</CitationRef>, <CitationRef CitationID="CR60_17">60</CitationRef>]. Moreover, androgens can activate HIF-1, driving VEGF expression in androgen-sensitive LNCaP cells. This regulation is mediated through an autocrine loop involving epidermal growth factor/phosphatidylinositol 3′-kinase/protein kinase B, which in turn activate HIF-1α and HIF-1-regulated gene expression [<CitationRef CitationID="CR61_17">61</CitationRef>]. In prostate cancer cells, the androgen receptor (AR) has been shown to enhance HIF-1-mediated gene expression and that HIF-1 interacts with the AR on the <Emphasis Type="Italic">PSA</Emphasis> gene promoter, thereby activating its expression [<CitationRef CitationID="CR62_17">62</CitationRef>]. Thus, HIF-1 might be involved in AR-mediated gene expression in prostate cancer and implicated in tumor growth and progression. Furthermore, single nucleotide polymorphisms (SNPs) in the oxygen-dependent degradation domain of the HIF-1α gene, which enhance HIF-1α activity and hence increase transcription of downstream angiogenesis-related genes, have been identified in prostate cancer cell lines and clinical samples [<CitationRef CitationID="CR63_17">63</CitationRef>]. One of the SNPs (P582S) is associated with an increased risk of prostate cancer [<CitationRef CitationID="CR64_17">64</CitationRef>, <CitationRef CitationID="CR65_17">65</CitationRef>]. Taken together, these findings indicate the importance of HIF-1-mediated VEGF and AR regulation in prostate tumorigenesis and identify HIF-1 as a possible prime target for prostate cancer therapy.</Para>
          </Section1>
          <Section1 ID="Sec6">
            <Heading>Antiangiogenic Therapy: Rationale and Classification</Heading>
            <Section2 ID="Sec7">
              <Heading>Rationale</Heading>
              <Para TextBreak="No">Antiangiogenic therapy stems from the fundamental concept that tumor growth, invasion, and metastatsis are angiogenesis-dependent. The microvascular EC recruited by a tumor has become an important second target in cancer therapy. Unlike the cancer cell (the primary target of cytotoxic chemotherapy) that is genetically unstable with unpredictable mutations, the genetic stability of ECs may make them less susceptible to acquired drug resistance [<CitationRef CitationID="CR66_17">66</CitationRef>]. Moreover, ECs in the microvascular bed of a tumor may support 50–100 tumor cells. Coupling this amplification potential together with the lower toxicity of most angiogenesis inhibitors results in the use of antiangiogenic therapy that should be significantly less toxic than conventional chemotherapy. Therefore, treating both the cancer cell and the EC in a tumor may be more effective than treating the cancer cell alone.</Para>
            </Section2>
            <Section2 ID="Sec8">
              <Heading>Classification of Antiangiogenic Agents</Heading>
              <Para TextBreak="No">The proof of concept that targeting angiogenesis is an effective strategy for treating cancer came with the approval of the first angiogenesis inhibitor, bevacizumab, by the US Food and Drug Admistration (FDA) following a phase III study showing a survival benefit. Since then, several antiangiogenesis agents have received FDA approval for cancer treatment and numerous investigational angiogenesis inhibitors currently are being tested in clinical trials of prostate cancer. The reader is referred to [<CitationRef CitationID="CR67_17">67</CitationRef>] for a general overview of the current state of drug development of angiogenesis inhibitors.</Para>
              <Para TextBreak="No">The inhibitors being investigated fall into several different categories, depending on their mechanism of action. Some inhibit ECs directly, while others inhibit the angiogenesis signaling cascade or block the ability of ECs to break down the extracellular matrix. Some antiangiogenic agents either target VEGF directly through neutralizing the protein, block the tumor expression of the angiogenic factor, or block the receptor for the angiogenic factor on the ECs. Finally, these inhibitors may also be characterized by the degree of their blocking potential: drugs that block one main angiogenic protein, drugs that block two or three main angiogenic proteins, or drugs that have a broad spectrum effect, blocking a range of angiogenic regulators [<CitationRef CitationID="CR67_17">67</CitationRef>]. These broad spectrum inhibitors may target the angiogenic regulators and/or signaling pathways in both the tumor and ECs.</Para>
              <Para TextBreak="No">There are two general classes of angiogenesis inhibitors. A <Emphasis Type="Italic">direct angiogenesis inhibitor</Emphasis> blocks vascular ECs from proliferating, migrating, or increasing their survival in response to proangiogenic proteins. Direct angiogenesis inhibitors are less likely to induce acquired drug resistance because they target the genetically stable ECs. Examples in this category include angiostatin and TSP-1. Other drugs, which interact with the integrin protein, also can promote the destruction of proliferating ECs. Integrins are cell surface adhesion molecules that play an essential role in cell–cell and cell–matrix adhesion. They are responsible for transmitting signals important for cell migration, invasion, proliferation, and survival. One member of the integrin family, α5β3-integrin, is expressed on tumor and ECs. The involvement of integrin in tumor angiogenesis was demonstrated in studies that show the β4 subunit of integrin promoting endothelial migration and invasion [<CitationRef CitationID="CR68_17">68</CitationRef>].</Para>
              <Para TextBreak="No">
                <Emphasis Type="Italic">Indirect angiogenesis inhibitors</Emphasis> decrease or block the expression of a tumor cell product, neutralize the tumor product itself, or block its receptor on ECs. Examples of drugs that interfere with the angiogenesis signaling pathway include bevacizumab, sorafenib, and sunitinab. These drugs target the major signaling pathways in tumor angiogenesis: VEGF, PDGF, and their respective receptors as well as other growth factors and/or signaling pathways. As such, most indirect angiogenesis inhibitors are designed to target these signaling pathways and can block the activity of one, two, or a broad spectrum of proangiogenic proteins and/or their receptors. The limitation to indirect inhibitors is that over time tumor cells may acquire mutations that lead to increased expression of other proangiogenic proteins not blocked by the indirect inhibitor. This may give the appearance of drug resistance and warrants the addition of a second antiangiogenic agent, one that would target the expression of these upregulated proangiogenic proteins.</Para>
              <Para TextBreak="No">Angiogenesis inhibitors may also be referred to as either being <Emphasis Type="Italic">exclusive</Emphasis> or <Emphasis Type="Italic">inclusive</Emphasis>. Drugs that are <Emphasis Type="Italic">exclusively</Emphasis> antiangiogenic only have one known function, which is to exhibit antiangiogenic activity. Examples of these drugs include bevacizumab, VEGF-Trap, etc. For other angiogenesis inhibitors, the antiangiogenic activity is <Emphasis Type="Italic">included</Emphasis> with other functions of the drug. Among them are certain cancer agents that exhibit dual roles. In many cases, the antiangiogenic activity is discovered as a secondary function after the drug has received FDA approval for a different primary function. For example, bortezomib is a proteasome inhibitor that is approved for multiple myeloma and later found to possess antiangiogenic acitivity via inhibiting VEGF. Certain orally available small molecule drugs display their antiangiogenic activity through inducing the expression of endogenous angiogenesis inhibitors such as celecoxib, a cox-2 inhibitor, which inhibits angiogenesis by increasing levels of endostatin [<CitationRef CitationID="CR30_17">30</CitationRef>]. Both bortezomib and celecoxib are under clinical investigation as potential angiogenesis inhibitors in prostate cancer clinical trials.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec9">
            <Heading>Combination Therapies</Heading>
            <Para TextBreak="No">Tumor angiogenesis is a highly complex process involving multiple growth factors and their receptor signaling pathways. Based on current evidence, with a few exceptions, effective therapy will probably rely on a combinatorial approach that involves targeting multiple pathways simultaneously. A number of studies have shown that antiangiogenic agents in combination with chemotherapy or radiotherapy result in additive or synergistic effects. Several models have been proposed to explain the mechanism responsible for this potentiation, keying in on the chemosensitizing effects of antiangiogenic therapy [<CitationRef CitationID="CR69_17">69</CitationRef>]. One hypothesis is that antiangiogenic therapy may normalize the tumor vasculature, thus resulting in improved oxygenation, better blood perfusion and, consequently, improved delivery of chemotherapeutic drugs [<CitationRef CitationID="CR70_17">70</CitationRef>]. A second model suggests that chemotherapy delivered at low doses and at close, regular intervals with no extended drug-free break periods preferentially damages ECs in the tumor neovasculature [<CitationRef CitationID="CR71_17">71</CitationRef>, <CitationRef CitationID="CR72_17">72</CitationRef>] and suppresses circulating endothelial progenitor cells [<CitationRef CitationID="CR73_17">73</CitationRef>, <CitationRef CitationID="CR74_17">74</CitationRef>]. This regimen, also called metronomic chemotherapy, sustains antiangiogenic activity and reduces acute toxicity [<CitationRef CitationID="CR75_17">75</CitationRef>]. Thus, the efficacy of metronomic chemotherapy may increase when administered in combination with specific antiangiogenic drugs. Finally, the third model addresses the use of antiangiogenic drugs to slow down tumor cell repopulation between successive cycles of cytotoxic chemotherapy [<CitationRef CitationID="CR76_17">76</CitationRef>]. This model underscores the importance of timing and sequence in achieving the maximal therapeutic benefit from combination therapies. Nevertheless, it remains a challenge to establish the most effective timing and combination of antiangiogenic agents, other targeted therapies, and conventional therapies to improve clinical outcomes, particularly in patients with CRPC who become refractory to docetaxel chemotherapy.</Para>
          </Section1>
          <Section1 ID="Sec10">
            <Heading>Surrogate Markers of Antiangiogenic Therapy</Heading>
            <Para TextBreak="No">Antiangiogenesis therapy has created a need to develop effective biomarkers to assess the activity of these inhibitors. Surrogate markers of tumor angiogenesis activity are important to guide clinical development of these agents and to select patients most likely to benefit from this approach. Several avenues are currently being investigated and include tumor biopsy analysis, MVD, noninvasive vascular imaging (positron emission tomography, MRI) and measuring circulating biomarkers (levels of angiogenic factors in serum, plasma, urine, or circulating ECs) [<CitationRef CitationID="CR77_17">77</CitationRef>]. Thus, reliable surrogate markers of activity are desparately needed to monitor and evaluate the clinical efficacy of these new drugs.</Para>
          </Section1>
          <Section1 ID="Sec11">
            <Heading>Resistance to Antiangiogenic Therapy</Heading>
            <Para TextBreak="No">Resistance to VEGF inhibitors may be observed in late stage tumors when tumors re-grow during treatment, after an initial period of growth suppression from these antiangiogenic agents. This resistance to VEGF inhibitors involves reactivation of tumor angiogenesis and increased expression of other proangiogenic factors. As the disease progresses, it is possible that redundant pathways might be implicated, with VEGF being replaced by other angiogenic pathways, warranting the addition of a second antiangiogenesis agent that would target these secondary growth factors and/or their activated receptor pathways. Perhaps the administration of angiogenic drugs at earlier stages of the disease may be a more effective and beneficial approach. In addition, tumor cells bearing genetic alterations of the <Emphasis Type="Italic">p53</Emphasis> gene may display a lower apoptosis rate under hypoxic conditions, which might reduce their reliance on vascular supply and thereby their responsiveness to antiangiogenic therapy [<CitationRef CitationID="CR78_17">78</CitationRef>]. Therefore, the selection and overgrowth of tumor-variant cells that are hypoxia resistant and thus less dependent [<CitationRef CitationID="CR78_17">78</CitationRef>] on angiogenesis and vasculature remodeling resulting in vessel stabilization [<CitationRef CitationID="CR79_17">79</CitationRef>] could also explain the resistance to antiangiogenic drugs. Finally, among the possible mechanisms for acquired resistance to antiangiogenic drugs [<CitationRef CitationID="CR80_17">80</CitationRef>, <CitationRef CitationID="CR81_17">81</CitationRef>] perhaps the most intriguing finding is that although ECs are assumed to be genetically stable, they may under some circumstances harbor genetic abnormalities and thus acquire resistance as well [<CitationRef CitationID="CR82_17">82</CitationRef>, <CitationRef CitationID="CR83_17">83</CitationRef>].</Para>
          </Section1>
          <Section1 ID="Sec12" Type="Conclusion">
            <Heading>Conclusion</Heading>
            <Para TextBreak="No">Antiangiogenic therapy has been established as a fourth modality in cancer treatment validating that angiogenesis as an important target for cancer. The role of angiogenesis in prostate cancer is well established, and the inhibition of this process has been shown to suppress tumor growth and metastasis in both preclinical prostate cancer models and in current clinical studies. Angiogenesis inhibition is likely to be a part of standard treatment strategy for CaP in the near future. Hence, current research efforts are needed to develop better surrogate markers of tumor angiogenesis and selection markers, determine the optimal dosing strategy, define the target patient population, and identify the most effective combination therapy to ensure that patients will fully benefit from these new agents as well as determine the tumor types and stages that will benefit most from antiangiogenic therapy. Much progress is needed in understanding the emergence of targeted therapy resistance and assessing the potential cumulative toxicities that arise from combination therapies of multiple antiangiogenic regimens. Nonetheless, while chemotherapy will remain a mainstay of cancer treatment for years to come, antiangiogenic therapy represents a promising add-on strategy for the treatment of prostate cancer for patients with CRPC.</Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-829-4_Chapter_17.pdf" OutputMedium="Online" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1_17">
              <CitationNumber>1</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AG</Initials>
                  <FamilyName>Ide</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NH</Initials>
                  <FamilyName>Baker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SL</Initials>
                  <FamilyName>Warren</FamilyName>
                </BibAuthorName>
                <Year>1939</Year>
                <ArticleTitle Language="En">Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamger</ArticleTitle>
                <JournalTitle>Am J Roentgenol</JournalTitle>
                <VolumeID>42</VolumeID>
                <FirstPage>891</FirstPage>
                <LastPage>9</LastPage>
              </BibArticle>
              <BibUnstructured>Ide AG, Baker NH, Warren SL. Vascularization of the Brown Pearce rabbit epithelioma transplant as seen in the transparent ear chamger. Am J Roentgenol 1939;42:891–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR2_17">
              <CitationNumber>2</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GH</Initials>
                  <FamilyName>Algire</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HW</Initials>
                  <FamilyName>Chalkley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FY</Initials>
                  <FamilyName>Legallais</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HD</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <Year>1945</Year>
                <ArticleTitle Language="En">Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>73</FirstPage>
                <LastPage>85</LastPage>
              </BibArticle>
              <BibUnstructured>Algire GH, Chalkley HW, Legallais FY, Park HD. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR3_17">
              <CitationNumber>3</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Merler</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Abernathy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Williams</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Isolation of a tumor factor responsible for angiogenesis</ArticleTitle>
                <JournalTitle>J Exp Med</JournalTitle>
                <VolumeID>133</VolumeID>
                <FirstPage>275</FirstPage>
                <LastPage>88</LastPage>
                <Occurrence Type="PID">
                  <Handle>4332371</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1084/jem.133.2.275</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE38%2Fot1SgsA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275–88.</BibUnstructured>
            </Citation>
            <Citation ID="CR4_17">
              <CitationNumber>4</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1971</Year>
                <ArticleTitle Language="En">Tumor angiogenesis: therapeutic implications</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>285</VolumeID>
                <FirstPage>1182</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>4938153</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM197108122850711</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaE38%2FgvVCqsQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR5_17">
              <CitationNumber>5</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Papetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IM</Initials>
                  <FamilyName>Herman</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Mechanisms of normal and tumor-derived angiogenesis</ArticleTitle>
                <JournalTitle>Am J Physiol Cell Physiol</JournalTitle>
                <VolumeID>282</VolumeID>
                <FirstPage>C947</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>11940508</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1152/ajpcell.00389.2001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XjslWltL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR6_17">
              <CitationNumber>6</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Hanahan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1996</Year>
                <ArticleTitle Language="En">Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>353</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="PID">
                  <Handle>8756718</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(00)80108-7</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK28XltVSks7s%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR7_17">
              <CitationNumber>7</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>WC</Initials>
                  <FamilyName>Black</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HG</Initials>
                  <FamilyName>Welch</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>328</VolumeID>
                <FirstPage>1237</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="PID">
                  <Handle>8464435</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199304293281706</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3s3hvVKluw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Black WC, Welch HG. Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy. N Engl J Med 1993;328:1237–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR8_17">
              <CitationNumber>8</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kalluri</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Cancer without disease</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>427</VolumeID>
                <FirstPage>787</FirstPage>
                <Occurrence Type="PID">
                  <Handle>14985739</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/427787a</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhsFCju7c%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J, Kalluri R. Cancer without disease. Nature 2004;427:787.</BibUnstructured>
            </Citation>
            <Citation ID="CR9_17">
              <CitationNumber>9</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JP</Initials>
                  <FamilyName>Semple</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>WR</Initials>
                  <FamilyName>Welch</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>324</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>1701519</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJM199101033240101</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3M%2FnsVWquw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis – correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR10_17">
              <CitationNumber>10</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Udagawa</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Fernandez</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EG</Initials>
                  <FamilyName>Achilles</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RJ</Initials>
                  <FamilyName>D'Amato</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy</ArticleTitle>
                <JournalTitle>FASEB J</JournalTitle>
                <VolumeID>16</VolumeID>
                <FirstPage>1361</FirstPage>
                <LastPage>70</LastPage>
                <Occurrence Type="PID">
                  <Handle>12205027</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1096/fj.01-0813com</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XntFWmt7k%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Udagawa T, Fernandez A, Achilles EG, Folkman J, D’Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J 2002;16:1361–70.</BibUnstructured>
            </Citation>
            <Citation ID="CR11_17">
              <CitationNumber>11</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GN</Initials>
                  <FamilyName>Naumov</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Bender</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Zurakowski</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>98</VolumeID>
                <FirstPage>316</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>16507828</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/djj068</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006;98:316–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR12_17">
              <CitationNumber>12</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Holmgren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>O’Reilly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>149</FirstPage>
                <LastPage>53</LastPage>
                <Occurrence Type="PID">
                  <Handle>7585012</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0295-149</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXksVeru78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holmgren L, O’Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149–53.</BibUnstructured>
            </Citation>
            <Citation ID="CR13_17">
              <CitationNumber>13</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Holash</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PC</Initials>
                  <FamilyName>Maisonpierre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Compton</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1999</Year>
                <ArticleTitle Language="En">Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>284</VolumeID>
                <FirstPage>1994</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>10373119</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.284.5422.1994</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1MXktVWntrY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR14_17">
              <CitationNumber>14</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Relf</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>LeJeune</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PA</Initials>
                  <FamilyName>Scott</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>57</VolumeID>
                <FirstPage>963</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>9041202</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXhs1Khsrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57:963–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR15_17">
              <CitationNumber>15</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Ferrara</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HP</Initials>
                  <FamilyName>Gerber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>LeCouter</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">The biology of VEGF and its receptors</ArticleTitle>
                <JournalTitle>Nat Med</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>669</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="PID">
                  <Handle>12778165</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nm0603-669</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXktFOnur4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR16_17">
              <CitationNumber>16</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Lindahl</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Johansson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Leveen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Betsholtz</FamilyName>
                </BibAuthorName>
                <Year>1997</Year>
                <ArticleTitle Language="En">Pericyte loss and microaneurysm formation in PDGF-B-deficient mice</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>277</VolumeID>
                <FirstPage>242</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>9211853</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.277.5323.242</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2sXksFCksb0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR17_17">
              <CitationNumber>17</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Oliner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Min</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Leal</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>507</FirstPage>
                <LastPage>16</LastPage>
                <Occurrence Type="PID">
                  <Handle>15542434</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ccr.2004.09.030</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVGlurjP</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004;6:507–16.</BibUnstructured>
            </Citation>
            <Citation ID="CR18_17">
              <CitationNumber>18</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Carmeliet</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Dor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JM</Initials>
                  <FamilyName>Herbert</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1998</Year>
                <ArticleTitle Language="En">Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>394</VolumeID>
                <FirstPage>485</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>9697772</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/28867</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK1cXltVGqsbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR19_17">
              <CitationNumber>19</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Endogenous angiogenesis inhibitors</ArticleTitle>
                <JournalTitle>APMIS</JournalTitle>
                <VolumeID>112</VolumeID>
                <FirstPage>496</FirstPage>
                <LastPage>507</LastPage>
                <Occurrence Type="PID">
                  <Handle>15563312</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1600-0463.2004.apm11207-0809.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXls1Ghtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Endogenous angiogenesis inhibitors. APMIS 2004;112:496–507.</BibUnstructured>
            </Citation>
            <Citation ID="CR20_17">
              <CitationNumber>20</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Nyberg</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Xie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Kalluri</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Endogenous inhibitors of angiogenesis</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>65</VolumeID>
                <FirstPage>3967</FirstPage>
                <LastPage>79</LastPage>
                <Occurrence Type="PID">
                  <Handle>15899784</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-2427</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktlSms7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nyberg P, Xie L, Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005;65:3967–79.</BibUnstructured>
            </Citation>
            <Citation ID="CR21_17">
              <CitationNumber>21</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Klement</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Oncogenes and angiogenesis: signaling three-dimensional tumor growth</ArticleTitle>
                <JournalTitle>J Investig Dermatol Symp Proc</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>24</FirstPage>
                <LastPage>33</LastPage>
                <Occurrence Type="PID">
                  <Handle>11147671</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1087-0024.2000.00012.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXhtVeltbg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:24–33.</BibUnstructured>
            </Citation>
            <Citation ID="CR22_17">
              <CitationNumber>22</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Brouty-Boye</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BR</Initials>
                  <FamilyName>Zetter</FamilyName>
                </BibAuthorName>
                <Year>1980</Year>
                <ArticleTitle Language="En">Inhibition of cell motility by interferon</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>208</VolumeID>
                <FirstPage>516</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>6154315</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.6154315</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL3cXkt1Chsrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Brouty-Boye D, Zetter BR. Inhibition of cell motility by interferon. Science 1980;208:516–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR23_17">
              <CitationNumber>23</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HF</Initials>
                  <FamilyName>Dvorak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Gresser</FamilyName>
                </BibAuthorName>
                <Year>1989</Year>
                <ArticleTitle Language="En">Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice</ArticleTitle>
                <JournalTitle>J Natl Cancer Inst</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>497</FirstPage>
                <LastPage>502</LastPage>
                <Occurrence Type="PID">
                  <Handle>2921774</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1093/jnci/81.7.497</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL1MXitFSlsr4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dvorak HF, Gresser I. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice. J Natl Cancer Inst 1989;81:497–502.</BibUnstructured>
            </Citation>
            <Citation ID="CR24_17">
              <CitationNumber>24</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>YA</Initials>
                  <FamilyName>Sidky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EC</Initials>
                  <FamilyName>Borden</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>47</VolumeID>
                <FirstPage>5155</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>2441862</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL2sXmtFGqsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 1987;47:5155–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR25_17">
              <CitationNumber>25</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Taylor</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1982</Year>
                <ArticleTitle Language="En">Protamine is an inhibitor of angiogenesis</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>297</VolumeID>
                <FirstPage>307</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>6176876</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/297307a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL38XlsFKjsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Taylor S, Folkman J. Protamine is an inhibitor of angiogenesis. Nature 1982;297:307–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR26_17">
              <CitationNumber>26</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Crum</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Szabo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1985</Year>
                <ArticleTitle Language="En">A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>230</VolumeID>
                <FirstPage>1375</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>2416056</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.2416056</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XivV2nuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985;230:1375–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR27_17">
              <CitationNumber>27</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Ingber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Fujita</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Kishimoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1990</Year>
                <ArticleTitle Language="En">Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth</ArticleTitle>
                <JournalTitle>Nature</JournalTitle>
                <VolumeID>348</VolumeID>
                <FirstPage>555</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>1701033</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/348555a0</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3MXpsVOntw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR28_17">
              <CitationNumber>28</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>O’Reilly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Holmgren</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shing</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1994</Year>
                <ArticleTitle Language="En">Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>315</FirstPage>
                <LastPage>28</LastPage>
                <Occurrence Type="PID">
                  <Handle>7525077</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0092-8674(94)90200-3</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315–28.</BibUnstructured>
            </Citation>
            <Citation ID="CR29_17">
              <CitationNumber>29</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>O’Reilly</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Boehm</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Shing</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>1997</Year>
                <ArticleTitle Language="En">Endostatin: an endogenous inhibitor of angiogenesis and tumor growth</ArticleTitle>
                <JournalTitle>Cell</JournalTitle>
                <VolumeID>88</VolumeID>
                <FirstPage>277</FirstPage>
                <LastPage>85</LastPage>
                <Occurrence Type="PID">
                  <Handle>9008168</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0092-8674(00)81848-6</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277–85.</BibUnstructured>
            </Citation>
            <Citation ID="CR30_17">
              <CitationNumber>30</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Antiangiogenesis in cancer therapy – endostatin and its mechanisms of action</ArticleTitle>
                <JournalTitle>Exp Cell Res</JournalTitle>
                <VolumeID>312</VolumeID>
                <FirstPage>594</FirstPage>
                <LastPage>607</LastPage>
                <Occurrence Type="PID">
                  <Handle>16376330</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.yexcr.2005.11.015</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XhvVWltbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Antiangiogenesis in cancer therapy – endostatin and its mechanisms of action. Exp Cell Res 2006;312:594–607.</BibUnstructured>
            </Citation>
            <Citation ID="CR31_17">
              <CitationNumber>31</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Lawler</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth</ArticleTitle>
                <JournalTitle>J Cell Mol Med</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1</FirstPage>
                <LastPage>12</LastPage>
                <Occurrence Type="PID">
                  <Handle>12003665</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1111/j.1582-4934.2002.tb00307.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XksVCjt74%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. J Cell Mol Med 2002;6:1–12.</BibUnstructured>
            </Citation>
            <Citation ID="CR32_17">
              <CitationNumber>32</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Maeshima</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Manfredi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Reimer</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin</ArticleTitle>
                <JournalTitle>J Biol Chem</JournalTitle>
                <VolumeID>276</VolumeID>
                <FirstPage>15240</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11278365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1074/jbc.M007764200</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXjs1Ortrc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Maeshima Y, Manfredi M, Reimer C, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001;276:15240–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR33_17">
              <CitationNumber>33</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Sund</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hamano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Sugimoto</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors</ArticleTitle>
                <JournalTitle>Proc Natl Acad Sci U S A</JournalTitle>
                <VolumeID>102</VolumeID>
                <FirstPage>2934</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15710885</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1073/pnas.0500180102</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXitVSktrg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sund M, Hamano Y, Sugimoto H, et al. Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. Proc Natl Acad Sci U S A 2005;102:2934–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR34_17">
              <CitationNumber>34</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>KM</Initials>
                  <FamilyName>Dameron</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>OV</Initials>
                  <FamilyName>Volpert</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MA</Initials>
                  <FamilyName>Tainsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Bouck</FamilyName>
                </BibAuthorName>
                <Year>1994</Year>
                <ArticleTitle Language="En">Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>265</VolumeID>
                <FirstPage>1582</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>7521539</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.7521539</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2cXmtVajtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR35_17">
              <CitationNumber>35</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Zhang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Hu</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>3655</FirstPage>
                <LastPage>61</LastPage>
                <Occurrence Type="PID">
                  <Handle>10910082</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXkvFChtr0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhang L, Yu D, Hu M, et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res 2000;60:3655–61.</BibUnstructured>
            </Citation>
            <Citation ID="CR36_17">
              <CitationNumber>36</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>ZA</Initials>
                  <FamilyName>Sherif</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Nakai</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KF</Initials>
                  <FamilyName>Pirollo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Rait</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EH</Initials>
                  <FamilyName>Chang</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Downmodulation of bFGF-binding protein expression following restoration of p53 function</ArticleTitle>
                <JournalTitle>Cancer Gene Ther</JournalTitle>
                <VolumeID>8</VolumeID>
                <FirstPage>771</FirstPage>
                <LastPage>82</LastPage>
                <Occurrence Type="PID">
                  <Handle>11687900</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.cgt.7700361</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXnvVejsbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sherif ZA, Nakai S, Pirollo KF, Rait A, Chang EH. Downmodulation of bFGF-binding protein expression following restoration of p53 function. Cancer Gene Ther 2001;8:771–82.</BibUnstructured>
            </Citation>
            <Citation ID="CR37_17">
              <CitationNumber>37</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Ravi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mookerjee</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>ZM</Initials>
                  <FamilyName>Bhujwalla</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha</ArticleTitle>
                <JournalTitle>Genes Dev</JournalTitle>
                <VolumeID>14</VolumeID>
                <FirstPage>34</FirstPage>
                <LastPage>44</LastPage>
                <Occurrence Type="PID">
                  <Handle>10640274</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXntFGkuw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34–44.</BibUnstructured>
            </Citation>
            <Citation ID="CR38_17">
              <CitationNumber>38</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JG</Initials>
                  <FamilyName>Teodoro</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AE</Initials>
                  <FamilyName>Parker</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>X</Initials>
                  <FamilyName>Zhu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Green</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>313</VolumeID>
                <FirstPage>968</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>16917063</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1126391</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XotFCitLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Teodoro JG, Parker AE, Zhu X, Green MR. p53-mediated inhibition of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 2006;313:968–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR39_17">
              <CitationNumber>39</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin</ArticleTitle>
                <JournalTitle>Sci STKE</JournalTitle>
                <VolumeID>2006</VolumeID>
                <FirstPage>pe35</FirstPage>
                <Occurrence Type="PID">
                  <Handle>17003465</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/stke.3542006pe35</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Tumor suppression by p53 is mediated in part by the antiangiogenic activity of endostatin and tumstatin. Sci STKE 2006;2006:pe35.</BibUnstructured>
            </Citation>
            <Citation ID="CR40_17">
              <CitationNumber>40</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AV</Initials>
                  <FamilyName>Bono</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Celato</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>V</Initials>
                  <FamilyName>Cova</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Salvadore</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Chinetti</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Novario</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Microvessel density in prostate carcinoma</ArticleTitle>
                <JournalTitle>Prostate Cancer Prostatic Dis</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>123</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>12497001</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.pcan.4500572</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD38jjsVCltQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bono AV, Celato N, Cova V, Salvadore M, Chinetti S, Novario R. Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002;5:123–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR41_17">
              <CitationNumber>41</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BV</Initials>
                  <FamilyName>Offersen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nerstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>1998</Year>
                <ArticleTitle Language="En">Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>78</VolumeID>
                <FirstPage>940</FirstPage>
                <LastPage>4</LastPage>
                <Occurrence Type="PID">
                  <Handle>9764587</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/bjc.1998.605</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1cvjsFKitA%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borre M, Offersen BV, Nerstrom B, Overgaard J. Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998;78:940–4.</BibUnstructured>
            </Citation>
            <Citation ID="CR42_17">
              <CitationNumber>42</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>N</Initials>
                  <FamilyName>Weidner</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR</Initials>
                  <FamilyName>Carroll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Flax</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Blumenfeld</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ArticleTitle Language="En">Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma</ArticleTitle>
                <JournalTitle>Am J Pathol</JournalTitle>
                <VolumeID>143</VolumeID>
                <FirstPage>401</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>7688183</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK3szktlWqtQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143:401–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR43_17">
              <CitationNumber>43</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Borre</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Nerstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Overgaard</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1882</FirstPage>
                <LastPage>90</LastPage>
                <Occurrence Type="PID">
                  <Handle>10815911</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvhtVOgug%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000;6:1882–90.</BibUnstructured>
            </Citation>
            <Citation ID="CR44_17">
              <CitationNumber>44</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Kuniyasu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Troncoso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Johnston</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>2295</FirstPage>
                <LastPage>308</LastPage>
                <Occurrence Type="PID">
                  <Handle>10873080</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXksVGhs7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kuniyasu H, Troncoso P, Johnston D, et al. Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers. Clin Cancer Res 2000;6:2295–308.</BibUnstructured>
            </Citation>
            <Citation ID="CR45_17">
              <CitationNumber>45</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Duque</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KR</Initials>
                  <FamilyName>Loughlin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RM</Initials>
                  <FamilyName>Adam</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PW</Initials>
                  <FamilyName>Kantoff</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Zurakowski</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MR</Initials>
                  <FamilyName>Freeman</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer</ArticleTitle>
                <JournalTitle>Urology</JournalTitle>
                <VolumeID>54</VolumeID>
                <FirstPage>523</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10475365</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0090-4295(99)00167-3</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK1Mvgt1emsg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR46_17">
              <CitationNumber>46</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>GE</Initials>
                  <FamilyName>Meyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JA</Initials>
                  <FamilyName>Siegal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JC</Initials>
                  <FamilyName>Petteway</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Blumenstein</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MK</Initials>
                  <FamilyName>Brawer</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Serum basic fibroblast growth factor in men with and without prostate carcinoma</ArticleTitle>
                <JournalTitle>Cancer</JournalTitle>
                <VolumeID>76</VolumeID>
                <FirstPage>2304</FirstPage>
                <LastPage>11</LastPage>
                <Occurrence Type="PID">
                  <Handle>8635036</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0142(19951201)76:11&lt;2304::AID-CNCR2820761119&gt;3.0.CO;2-N</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK283itlartw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA, Brawer MK. Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 1995;76:2304–11.</BibUnstructured>
            </Citation>
            <Citation ID="CR47_17">
              <CitationNumber>47</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Trojan</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Thomas</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Knoll</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Grobholz</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Alken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MS</Initials>
                  <FamilyName>Michel</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer</ArticleTitle>
                <JournalTitle>Urol Res</JournalTitle>
                <VolumeID>32</VolumeID>
                <FirstPage>97</FirstPage>
                <LastPage>103</LastPage>
                <Occurrence Type="PID">
                  <Handle>15250102</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1007/s00240-003-0383-5</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXltVKnurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Trojan L, Thomas D, Knoll T, Grobholz R, Alken P, Michel MS. Expression of pro-angiogenic growth factors VEGF, EGF and bFGF and their topographical relation to neovascularisation in prostate cancer. Urol Res 2004;32:97–103.</BibUnstructured>
            </Citation>
            <Citation ID="CR48_17">
              <CitationNumber>48</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>AF</Initials>
                  <FamilyName>West</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>O’Donnell</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Charlton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DE</Initials>
                  <FamilyName>Neal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>HY</Initials>
                  <FamilyName>Leung</FamilyName>
                </BibAuthorName>
                <Year>2001</Year>
                <ArticleTitle Language="En">Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>85</VolumeID>
                <FirstPage>576</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>11506499</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1054/bjoc.2001.1971</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3MXmvFKks7w%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>West AF, O’Donnell M, Charlton RG, Neal DE, Leung HY. Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. Br J Cancer 2001;85:576–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR49_17">
              <CitationNumber>49</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Lehrer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EJ</Initials>
                  <FamilyName>Diamond</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Mamkine</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NN</Initials>
                  <FamilyName>Stone</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RG</Initials>
                  <FamilyName>Stock</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Serum interleukin-8 is elevated in men with prostate cancer and bone metastases</ArticleTitle>
                <JournalTitle>Technol Cancer Res Treat</JournalTitle>
                <VolumeID>3</VolumeID>
                <FirstPage>411</FirstPage>
                <Occurrence Type="PID">
                  <Handle>15453805</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD2cvos1ynsQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.1177/153303460400300501</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol Cancer Res Treat 2004;3:411.</BibUnstructured>
            </Citation>
            <Citation ID="CR50_17">
              <CitationNumber>50</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Murphy</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>McGurk</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Pettigrew</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>11</VolumeID>
                <FirstPage>4117</FirstPage>
                <LastPage>27</LastPage>
                <Occurrence Type="PID">
                  <Handle>15930347</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1078-0432.CCR-04-1518</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXks1Gks7o%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005;11:4117–27.</BibUnstructured>
            </Citation>
            <Citation ID="CR51_17">
              <CitationNumber>51</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Wikstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Lissbrant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Stattin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Egevad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bergh</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>51</VolumeID>
                <FirstPage>268</FirstPage>
                <LastPage>75</LastPage>
                <Occurrence Type="PID">
                  <Handle>11987155</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.10083</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XltVSktbc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268–75.</BibUnstructured>
            </Citation>
            <Citation ID="CR52_17">
              <CitationNumber>52</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mehta</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Kyshtoobayeva</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Kurosaki</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Independent association of angiogenesis index with outcome in prostate cancer</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>81</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11205922</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M7lsFehtg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mehta R, Kyshtoobayeva A, Kurosaki T, et al. Independent association of angiogenesis index with outcome in prostate cancer. Clin Cancer Res 2001;7:81–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR53_17">
              <CitationNumber>53</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Strohmeyer</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Rossing</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bauerfeind</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>216</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>11074523</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20001101)45:3&lt;216::AID-PROS3&gt;3.0.CO;2-C</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXosFygsbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Strohmeyer D, Rossing C, Bauerfeind A, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostate cancer. Prostate 2000;45:216–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR54_17">
              <CitationNumber>54</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>IF</Initials>
                  <FamilyName>Lissbrant</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Stattin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Wikstrom</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JE</Initials>
                  <FamilyName>Damber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L</Initials>
                  <FamilyName>Egevad</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bergh</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival</ArticleTitle>
                <JournalTitle>Int J Oncol</JournalTitle>
                <VolumeID>17</VolumeID>
                <FirstPage>445</FirstPage>
                <LastPage>51</LastPage>
                <Occurrence Type="PID">
                  <Handle>10938382</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3M%2FjtVKnsQ%3D%3D</Handle>
                </Occurrence>
<Occurrence Type="DOI">
<Handle>10.3892/ijo.17.3.445</Handle>
</Occurrence>
              </BibArticle>
              <BibUnstructured>Lissbrant IF, Stattin P, Wikstrom P, Damber JE, Egevad L, Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000;17:445–51.</BibUnstructured>
            </Citation>
            <Citation ID="CR55_17">
              <CitationNumber>55</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Sivridis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Giatromanolaki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>I</Initials>
                  <FamilyName>Papadopoulos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KC</Initials>
                  <FamilyName>Gatter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AL</Initials>
                  <FamilyName>Harris</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MI</Initials>
                  <FamilyName>Koukourakis</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>86</VolumeID>
                <FirstPage>1465</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="PID">
                  <Handle>11986782</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6600281</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD383kslWltg%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sivridis E, Giatromanolaki A, Papadopoulos I, Gatter KC, Harris AL, Koukourakis MI. Thymidine phosphorylase expression in normal, hyperplastic and neoplastic prostates: correlation with tumour associated macrophages, infiltrating lymphocytes, and angiogenesis. Br J Cancer 2002;86:1465–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR56_17">
              <CitationNumber>56</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SA</Initials>
                  <FamilyName>Abdulkadir</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GF</Initials>
                  <FamilyName>Carvalhal</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Kaleem</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Tissue factor expression and angiogenesis in human prostate carcinoma</ArticleTitle>
                <JournalTitle>Hum Pathol</JournalTitle>
                <VolumeID>31</VolumeID>
                <FirstPage>443</FirstPage>
                <LastPage>7</LastPage>
                <Occurrence Type="PID">
                  <Handle>10821491</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1053/hp.2000.6547</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3c3nvFGisw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Abdulkadir SA, Carvalhal GF, Kaleem Z, et al. Tissue factor expression and angiogenesis in human prostate carcinoma. Hum Pathol 2000;31:443–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR57_17">
              <CitationNumber>57</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Du</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>C</Initials>
                  <FamilyName>Fujiyama</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Chen</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z</Initials>
                  <FamilyName>Masaki</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue</ArticleTitle>
                <JournalTitle>Chin Med J (Engl)</JournalTitle>
                <VolumeID>116</VolumeID>
                <FirstPage>1936</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhs1Gjtbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 2003;116:1936–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR58_17">
              <CitationNumber>58</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GL</Initials>
                  <FamilyName>Semenza</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>AM</Initials>
                  <FamilyName>Marzo</FamilyName>
                  <Particle>De</Particle>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis</ArticleTitle>
                <JournalTitle>Cancer Detect Prev</JournalTitle>
                <VolumeID>28</VolumeID>
                <FirstPage>88</FirstPage>
                <LastPage>93</LastPage>
                <Occurrence Type="PID">
                  <Handle>15068831</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.cdp.2003.12.009</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXkt12jtL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004;28:88–93.</BibUnstructured>
            </Citation>
            <Citation ID="CR59_17">
              <CitationNumber>59</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Mazzucchelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>R</Initials>
                  <FamilyName>Montironi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Santinelli</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Lucarini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Pugnaloni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Biagini</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>45</VolumeID>
                <FirstPage>72</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>10960845</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/1097-0045(20000915)45:1&lt;72::AID-PROS9&gt;3.0.CO;2-U</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DC%2BD3cvjvF2gtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mazzucchelli R, Montironi R, Santinelli A, Lucarini G, Pugnaloni A, Biagini G. Vascular endothelial growth factor expression and capillary architecture in high-grade PIN and prostate cancer in untreated and androgen-ablated patients. Prostate 2000;45:72–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR60_17">
              <CitationNumber>60</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DI</Initials>
                  <FamilyName>Quinn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Henshall</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RL</Initials>
                  <FamilyName>Sutherland</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Molecular markers of prostate cancer outcome</ArticleTitle>
                <JournalTitle>Eur J Cancer</JournalTitle>
                <VolumeID>41</VolumeID>
                <FirstPage>858</FirstPage>
                <LastPage>87</LastPage>
                <Occurrence Type="PID">
                  <Handle>15808955</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ejca.2004.12.035</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXjt1Wrtb4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer 2005;41:858–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR61_17">
              <CitationNumber>61</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Mabjeesh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MT</Initials>
                  <FamilyName>Willard</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Frederickson</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Zhong</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Simons</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells</ArticleTitle>
                <JournalTitle>Clin Cancer Res</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>2416</FirstPage>
                <LastPage>25</LastPage>
                <Occurrence Type="PID">
                  <Handle>12855613</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXlt1ykur0%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mabjeesh NJ, Willard MT, Frederickson CE, Zhong H, Simons JW. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 2003;9:2416–25.</BibUnstructured>
            </Citation>
            <Citation ID="CR62_17">
              <CitationNumber>62</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Horii</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Suzuki</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Kondo</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2007</Year>
                <ArticleTitle Language="En">Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells</ArticleTitle>
                <JournalTitle>Mol Cancer Res</JournalTitle>
                <VolumeID>5</VolumeID>
                <FirstPage>383</FirstPage>
                <LastPage>91</LastPage>
                <Occurrence Type="PID">
                  <Handle>17426252</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/1541-7786.MCR-06-0226</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjvFOksbo%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Horii K, Suzuki Y, Kondo Y, et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 2007;5:383–91.</BibUnstructured>
            </Citation>
            <Citation ID="CR63_17">
              <CitationNumber>63</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>XS</Initials>
                  <FamilyName>Fu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>E</Initials>
                  <FamilyName>Choi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GJ</Initials>
                  <FamilyName>Bubley</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SP</Initials>
                  <FamilyName>Balk</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>215</FirstPage>
                <LastPage>21</LastPage>
                <Occurrence Type="PID">
                  <Handle>15538748</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20190</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXktFylt7Y%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Fu XS, Choi E, Bubley GJ, Balk SP. Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005;63:215–21.</BibUnstructured>
            </Citation>
            <Citation ID="CR64_17">
              <CitationNumber>64</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CH</Initials>
                  <FamilyName>Chau</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>MG</Initials>
                  <FamilyName>Permenter</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>SM</Initials>
                  <FamilyName>Steinberg</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer</ArticleTitle>
                <JournalTitle>Cancer Biol Ther</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>1222</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>16205110</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvFGhtLk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Chau CH, Permenter MG, Steinberg SM, et al. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol Ther 2005;4:1222–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR65_17">
              <CitationNumber>65</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Orr-Urtreger</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Bar-Shira</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>H</Initials>
                  <FamilyName>Matzkin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NJ</Initials>
                  <FamilyName>Mabjeesh</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer</ArticleTitle>
                <JournalTitle>Prostate</JournalTitle>
                <VolumeID>67</VolumeID>
                <FirstPage>8</FirstPage>
                <LastPage>13</LastPage>
                <Occurrence Type="PID">
                  <Handle>16998808</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/pros.20433</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXhtVCrsL8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Orr-Urtreger A, Bar-Shira A, Matzkin H, Mabjeesh NJ. The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 alpha is associated with increased risk for prostate cancer. Prostate 2007;67:8–13.</BibUnstructured>
            </Citation>
            <Citation ID="CR66_17">
              <CitationNumber>66</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>1991</Year>
                <ArticleTitle Language="En">Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents</ArticleTitle>
                <JournalTitle>Bioessays</JournalTitle>
                <VolumeID>13</VolumeID>
                <FirstPage>31</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>1722975</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1002/bies.950130106</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaK387is1SitQ%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991;13:31–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR67_17">
              <CitationNumber>67</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Folkman</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Angiogenesis: an organizing principle for drug discovery?</ArticleTitle>
                <JournalTitle>Nat Rev Drug Discov</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>273</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>17396134</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrd2115</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2sXjs1SisL4%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6:273–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR68_17">
              <CitationNumber>68</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>SN</Initials>
                  <FamilyName>Nikolopoulos</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Blaikie</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Yoshioka</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W</Initials>
                  <FamilyName>Guo</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>FG</Initials>
                  <FamilyName>Giancotti</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Integrin beta4 signaling promotes tumor angiogenesis</ArticleTitle>
                <JournalTitle>Cancer Cell</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>471</FirstPage>
                <LastPage>83</LastPage>
                <Occurrence Type="PID">
                  <Handle>15542431</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ccr.2004.09.029</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhtVGlurjM</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Nikolopoulos SN, Blaikie P, Yoshioka T, Guo W, Giancotti FG. Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 2004;6:471–83.</BibUnstructured>
            </Citation>
            <Citation ID="CR69_17">
              <CitationNumber>69</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Antiangiogenic therapy: a universal chemosensitization strategy for cancer?</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>312</VolumeID>
                <FirstPage>1171</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="PID">
                  <Handle>16728631</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1125950</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XkvVOiur8%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006;312:1171–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR70_17">
              <CitationNumber>70</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RK</Initials>
                  <FamilyName>Jain</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>307</VolumeID>
                <FirstPage>58</FirstPage>
                <LastPage>62</LastPage>
                <Occurrence Type="PID">
                  <Handle>15637262</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1104819</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXnvFar</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58–62.</BibUnstructured>
            </Citation>
            <Citation ID="CR71_17">
              <CitationNumber>71</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>T</Initials>
                  <FamilyName>Browder</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>CE</Initials>
                  <FamilyName>Butterfield</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BM</Initials>
                  <FamilyName>Kraling</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>60</VolumeID>
                <FirstPage>1878</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>10766175</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXisVynurk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR72_17">
              <CitationNumber>72</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>G</Initials>
                  <FamilyName>Klement</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Baruchel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Rak</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2000</Year>
                <ArticleTitle Language="En">Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity</ArticleTitle>
                <JournalTitle>J Clin Invest</JournalTitle>
                <VolumeID>105</VolumeID>
                <FirstPage>R15</FirstPage>
                <LastPage>24</LastPage>
                <Occurrence Type="PID">
                  <Handle>10772661</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1172/JCI8829</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXisFOlurc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15–24.</BibUnstructured>
            </Citation>
            <Citation ID="CR73_17">
              <CitationNumber>73</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>F</Initials>
                  <FamilyName>Bertolini</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S</Initials>
                  <FamilyName>Paul</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mancuso</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2003</Year>
                <ArticleTitle Language="En">Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>63</VolumeID>
                <FirstPage>4342</FirstPage>
                <LastPage>6</LastPage>
                <Occurrence Type="PID">
                  <Handle>12907602</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmtFekurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Bertolini F, Paul S, Mancuso P, et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342–6.</BibUnstructured>
            </Citation>
            <Citation ID="CR74_17">
              <CitationNumber>74</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>P</Initials>
                  <FamilyName>Mancuso</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M</Initials>
                  <FamilyName>Colleoni</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Calleri</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2006</Year>
                <ArticleTitle Language="En">Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy</ArticleTitle>
                <JournalTitle>Blood</JournalTitle>
                <VolumeID>108</VolumeID>
                <FirstPage>452</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>16543470</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1182/blood-2005-11-4570</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XntFeht78%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Mancuso P, Colleoni M, Calleri A, et al. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006;108:452–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR75_17">
              <CitationNumber>75</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BA</Initials>
                  <FamilyName>Kamen</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">The anti-angiogenic basis of metronomic chemotherapy</ArticleTitle>
                <JournalTitle>Nat Rev Cancer</JournalTitle>
                <VolumeID>4</VolumeID>
                <FirstPage>423</FirstPage>
                <LastPage>36</LastPage>
                <Occurrence Type="PID">
                  <Handle>15170445</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/nrc1369</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXksVaisbk%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423–36.</BibUnstructured>
            </Citation>
            <Citation ID="CR76_17">
              <CitationNumber>76</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CA</Initials>
                  <FamilyName>Hudis</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Clinical implications of antiangiogenic therapies</ArticleTitle>
                <JournalTitle>Oncology (Williston Park)</JournalTitle>
                <VolumeID>19</VolumeID>
                <FirstPage>26</FirstPage>
                <LastPage>31</LastPage>
              </BibArticle>
              <BibUnstructured>Hudis CA. Clinical implications of antiangiogenic therapies. Oncology (Williston Park) 2005;19:26–31.</BibUnstructured>
            </Citation>
            <Citation ID="CR77_17">
              <CitationNumber>77</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DW</Initials>
                  <FamilyName>Davis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>McConkey</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Abbruzzese</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Herbst</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Surrogate markers in antiangiogenesis clinical trials</ArticleTitle>
                <JournalTitle>Br J Cancer</JournalTitle>
                <VolumeID>89</VolumeID>
                <FirstPage>8</FirstPage>
                <LastPage>14</LastPage>
                <Occurrence Type="PID">
                  <Handle>12838293</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/sj.bjc.6601035</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXltVWmsLc%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Davis DW, McConkey DJ, Abbruzzese JL, Herbst RS. Surrogate markers in antiangiogenesis clinical trials. Br J Cancer 2003;89:8–14.</BibUnstructured>
            </Citation>
            <Citation ID="CR78_17">
              <CitationNumber>78</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JL</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW</Initials>
                  <FamilyName>Rak</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BL</Initials>
                  <FamilyName>Coomber</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Hicklin</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <Year>2002</Year>
                <ArticleTitle Language="En">Effect of p53 status on tumor response to antiangiogenic therapy</ArticleTitle>
                <JournalTitle>Science</JournalTitle>
                <VolumeID>295</VolumeID>
                <FirstPage>1526</FirstPage>
                <LastPage>8</LastPage>
                <Occurrence Type="PID">
                  <Handle>11859195</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1126/science.1068327</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhsFyqtbY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526–8.</BibUnstructured>
            </Citation>
            <Citation ID="CR79_17">
              <CitationNumber>79</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Glade Bender</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EM</Initials>
                  <FamilyName>Cooney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JJ</Initials>
                  <FamilyName>Kandel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DJ</Initials>
                  <FamilyName>Yamashiro</FamilyName>
                </BibAuthorName>
                <Year>2004</Year>
                <ArticleTitle Language="En">Vascular remodeling and clinical resistance to antiangiogenic cancer therapy</ArticleTitle>
                <JournalTitle>Drug Resist Updat</JournalTitle>
                <VolumeID>7</VolumeID>
                <FirstPage>289</FirstPage>
                <LastPage>300</LastPage>
                <Occurrence Type="PID">
                  <Handle>15533766</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.drup.2004.09.001</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpsVOksrw%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Updat 2004;7:289–300.</BibUnstructured>
            </Citation>
            <Citation ID="CR80_17">
              <CitationNumber>80</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>CJ</Initials>
                  <FamilyName>Sweeney</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>KD</Initials>
                  <FamilyName>Miller</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GW</Initials>
                  <FamilyName>Sledge</FamilyName>
                  <Suffix>Jr</Suffix>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Resistance in the anti-angiogenic era: nay-saying or a word of caution?</ArticleTitle>
                <JournalTitle>Trends Mol Med</JournalTitle>
                <VolumeID>9</VolumeID>
                <FirstPage>24</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>12524207</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S1471-4914(02)00007-2</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3sXmsF2l</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sweeney CJ, Miller KD, Sledge GW, Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003;9:24–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR81_17">
              <CitationNumber>81</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>RS</Initials>
                  <FamilyName>Kerbel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Yu</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J</Initials>
                  <FamilyName>Tran</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2001</Year>
                <ArticleTitle Language="En">Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches</ArticleTitle>
                <JournalTitle>Cancer Metastasis Rev</JournalTitle>
                <VolumeID>20</VolumeID>
                <FirstPage>79</FirstPage>
                <LastPage>86</LastPage>
                <Occurrence Type="PID">
                  <Handle>11831651</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1023/A:1013172910858</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD38XhsVWlurs%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79–86.</BibUnstructured>
            </Citation>
            <Citation ID="CR82_17">
              <CitationNumber>82</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>B</Initials>
                  <FamilyName>Streubel</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>A</Initials>
                  <FamilyName>Chott</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Huber</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>351</VolumeID>
                <FirstPage>250</FirstPage>
                <LastPage>9</LastPage>
                <Occurrence Type="PID">
                  <Handle>15254283</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMoa033153</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXlslKrurg%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004;351:250–9.</BibUnstructured>
            </Citation>
            <Citation ID="CR83_17">
              <CitationNumber>83</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Hida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Y</Initials>
                  <FamilyName>Hida</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DN</Initials>
                  <FamilyName>Amin</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2004</Year>
                <ArticleTitle Language="En">Tumor-associated endothelial cells with cytogenetic abnormalities</ArticleTitle>
                <JournalTitle>Cancer Res</JournalTitle>
                <VolumeID>64</VolumeID>
                <FirstPage>8249</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="PID">
                  <Handle>15548691</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1158/0008-5472.CAN-04-1567</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXpvVGlurY%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64:8249–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR84_17">
              <CitationNumber>84</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>K</Initials>
                  <FamilyName>Walsh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RA</Initials>
                  <FamilyName>Sherwood</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>TK</Initials>
                  <FamilyName>Dew</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>D</Initials>
                  <FamilyName>Mulvin</FamilyName>
                </BibAuthorName>
                <Year>1999</Year>
                <ArticleTitle Language="En">Angiogenic peptides in prostatic disease</ArticleTitle>
                <JournalTitle>BJU Int</JournalTitle>
                <VolumeID>84</VolumeID>
                <FirstPage>1081</FirstPage>
                <LastPage>3</LastPage>
                <Occurrence Type="PID">
                  <Handle>10571640</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1046/j.1464-410x.1999.00363.x</Handle>
                </Occurrence>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXivValtw%3D%3D</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Walsh K, Sherwood RA, Dew TK, Mulvin D. Angiogenic peptides in prostatic disease. BJU Int 1999;84:1081–3.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Part>
  </Book>
</Publisher>
